Last reviewed · How we verify
Hepabulin IV
Hepabulin IV is a human serum albumin-based therapeutic that delivers heparin conjugate to provide anticoagulant and anti-inflammatory effects.
Hepabulin IV is a human serum albumin-based therapeutic that delivers heparin conjugate to provide anticoagulant and anti-inflammatory effects. Used for Thromboembolism prevention and treatment, Disseminated intravascular coagulation (DIC).
At a glance
| Generic name | Hepabulin IV |
|---|---|
| Sponsor | SK Chemicals Co., Ltd. |
| Drug class | Anticoagulant (albumin-heparin conjugate) |
| Target | Factor IIa (thrombin), Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Hematology |
| Phase | Phase 3 |
Mechanism of action
Hepabulin IV combines human serum albumin with heparin to create a stabilized complex that extends half-life and improves bioavailability compared to unmodified heparin. The albumin carrier allows for sustained delivery of anticoagulant activity while potentially reducing systemic side effects. This formulation is designed for intravenous administration in thrombotic and inflammatory conditions.
Approved indications
- Thromboembolism prevention and treatment
- Disseminated intravascular coagulation (DIC)
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |